Back
BridgeBio Pharma Quote, Financials, Valuation and Earnings
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
51
BBIO
BridgeBio Pharma
Last Price:
23.27
Seasonality Move:
7.7%
7 Day Trial
ALL ACCESS PASS
$
7
Access The Stock Grader Trading Tool From "The King Of Quants"
More details here...BridgeBio Pharma Price Quote
$23.27
+0.23 (+1%)
(Updated: November 21, 2024 at 5:55 PM ET)
BridgeBio Pharma Key Stats
Buy
51
BridgeBio Pharma (BBIO)
is a Buy
Day range:
$22.05 - $23.16
52-week range:
$21.62 - $44.32
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.71
P/B ratio:
0%
Volume:
1.4M
Avg. volume:
1.7M
1-year change:
-21.2%
Market cap:
$4.2B
Revenue:
$9.3M
EPS:
$-2.41
How Much Does BridgeBio Pharma Make?
-
How Much Are BridgeBio Pharma's Sales Annually?
BBIO Revenues are $9.3M -
How Much Profit Does BridgeBio Pharma's Make A Year?
BBIO net income is -$643.2M
Is BridgeBio Pharma Growing As A Company?
-
What Is BridgeBio Pharma's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.33% -
What Is BridgeBio Pharma's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
BridgeBio Pharma Stock Price Performance
-
Did BridgeBio Pharma Stock Go Up Last Month?
BridgeBio Pharma share price went down by -11.45% last month -
Did BBIO's Share Price Rise Over The Last Year?
BBIO share price fell by -21.2% over the past 1 year
What Is BridgeBio Pharma 52-Week High & Low?
-
What Is BridgeBio Pharma’s 52-Week High Share Price?
BridgeBio Pharma has traded as high as $44.32 over the past 52 weeks -
What Is BridgeBio Pharma’s 52-Week Low Share Price?
BridgeBio Pharma has traded as low as $21.62 over the past 52 weeks
BridgeBio Pharma Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy BridgeBio Pharma?
-
How Much Debt Does BridgeBio Pharma Have?
Total long term debt quarterly is $1.7B -
How Much Cash Does BridgeBio Pharma Have?
Cash and short term investments quarterly total is $266.3M -
What Is BridgeBio Pharma’s Book Value Per Share?
Book value per share is -6.51
Is BridgeBio Pharma Cash Flow Positive?
-
What Is BBIO Cash Flow From Operations?
Cash flow from operations (TTM) is -$450.2M -
What Is BridgeBio Pharma’s Cash Flow From Financing?
Cash flow from financing (TTM) is $270M -
What Is BridgeBio Pharma’s Cash Flow From Investing?
Cash flow from investing (TTM) is $64M
BridgeBio Pharma Return On Invested Capital
-
Is Management Doing A Good Job?
BBIO return on invested capital is -80.46% -
What Is BridgeBio Pharma Return On Assets?
ROA measures how assets are converting to revenues and is -62.51% -
What Is BBIO Return On Equity?
ROE is a measure of profitability and is 0%
BridgeBio Pharma Earnings Date & Stock Price
-
What Is BridgeBio Pharma's Stock Price Today?
A single share of BBIO can be purchased today for 23.04 -
What Is BridgeBio Pharma’s Stock Symbol?
BridgeBio Pharma trades on the nasdaq under the ticker symbol: BBIO -
When Is BridgeBio Pharma’s Next Earnings Date?
The next quarterly earnings date for BridgeBio Pharma is scheduled on February 21, 2025 -
When Is BBIO's next ex-dividend date?
BridgeBio Pharma's next ex-dividend date is November 22, 2024 -
How To Buy BridgeBio Pharma Stock?
You can buy BridgeBio Pharma shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
BridgeBio Pharma Competitors
-
Who Are BridgeBio Pharma's Competitors?
Below is a list of companies who compete with BridgeBio Pharma or are related in some way:
BridgeBio Pharma Dividend Yield
-
What Is BBIO Dividend Yield?
BridgeBio Pharma’s dividend yield currently is 0% -
What Is BridgeBio Pharma’s Payout Ratio?
BridgeBio Pharma’s payout ratio is 0% -
When Did BridgeBio Pharma Last Pay A Dividend?
The latest dividend pay date is November 22, 2024 -
What Is BridgeBio Pharma’s Dividend Per Share?
BridgeBio Pharma pays a dividend of $0.00 per share
BridgeBio Pharma Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -25.14% |
| Revenue: | -33.22% | -19.2% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 2 |
| Sell Recommendations: | 0 |
| Price Target: | 47.08 |
| Upside from Last Price: | 104.32% |